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Aims The objective of the present analysis was to systematically examine the effect of intracoronary bone marrow cell (BMC)
therapy on left ventricular (LV) function after ST-segment elevation myocardial infarction in various subgroups of patients
by performing a collaborative meta-analysis of randomized controlled trials.
Methods
and results
We identified all randomized controlled trials comparing intracoronary BMC infusion as treatment for ST-segment ele-
vation myocardial infarction. We contacted the principal investigator for each participating trial to provide summary data
with regard to different pre-specified subgroups [age, diabetes mellitus, time from symptoms to percutaneous coronary
intervention, infarct-related artery, LV end-diastolic volume index (EDVI), LV ejection fraction (EF), infarct size, presence
of microvascular obstruction, timing of cell infusion, and injected cell number] and three different endpoints [change in
LVEF, LVEDVI, and LV end-systolic volume index (ESVI)].
Data from 16 studies were combined including 1641 patients (984 cell therapy, 657 controls). The absolute improve-
ment in LVEF was greater among BMC-treated patients compared with controls: [2.55% increase, 95% confidence inter-
val (CI) 1.83–3.26, P, 0.001]. Cell therapy significantly reduced LVEDVI and LVESVI (23.17 mL/m2, 95% CI:24.86 to
21.47, P, 0.001;22.60 mL/m2, 95% CI23.84 to21.35, P, 0.001, respectively). Treatment benefit in terms of LVEF
improvement was more pronounced in younger patients (age ,55, 3.38%, 95% CI: 2.36–4.39) compared with older
patients (age ≥55 years, 1.77%, 95% CI: 0.80–2.74, P ¼ 0.03). This heterogeneity in treatment effect was also observed
with respect to the reduction in LVEDVI and LVESVI. Moreover, patients with baseline LVEF,40% derived more benefit
from intracoronary BMC therapy. LVEF improvement was 5.30%, 95% CI: 4.27–6.33 in patients with LVEF,40% com-
pared with 1.45%, 95% CI: 0.60 to 2.31 in LVEF≥40%, P, 0.001. No clear interaction was observed between other sub-
groups and outcomes.
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Conclusion Intracoronary BMC infusion is associated with improvement of LV function and remodelling in patients after ST-segment
elevation myocardial infarction. Younger patients and patients with a more severely depressed LVEF at baseline derived
most benefit from this adjunctive therapy.
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Introduction
Previous meta-analyses of randomized trials have shown that intra-
coronary bone marrow cell (BMC) infusion in ST-segment elevation
myocardial infarction (STEMI) patients has moderate positive results
on the recovery of left ventricular (LV) function.1,2 Based on more
detailed analyses from the individual trials, certain subgroups seem
to have more benefit.
In some studies, patients with long delay from onset symptoms to
revascularization, larger myocardial infarction (anterior myocardial
infarction) and reduced baseline LV ejection fraction (EF) were
more likely to benefit from BMC therapy.3– 5 Regarding microvascu-
lar obstruction (MVO), the subgroup effect remains unclear since
two studies reported different outcomes of BMC therapy in this
patients group.6,7 Furthermore, ageing and risk factors for coronary
artery disease affect the functional activity of endogenous stem and
progenitor cells in experimental models, thereby potentially limiting
the therapeutic potential of these cells.8
However, the individual trialshavenotbeen largeenoughtoexplore
outcomes reliably within such subgroups. Identifying the characteris-
tics of the patients who will ultimately benefit from cell therapy is es-
sential to allow for efficient translation of this novel therapy to
clinical practice. Therefore, the aim of this collaboration was to
assess the effects of intracoronary BMC on LVEF, LV end-diastolic
volume index (EDVI) and LV end-systolic volume index (ESVI) in
various subgroups of STEMI patients based on pooled patient data.
Methods
Data sources and study selection
We performed a computerized literature search from 1980 to February
2013 of the Pubmed, Embase, Cochrane database, the Current Con-
trolled Trials Register and KoreaMed, IndMed and LILACS by using
search terms that included ‘‘bone marrow cells’,“ “stem cell’’, ‘‘precursor
cell’’, ‘‘progenitor cell’’, ‘‘myocardial ischaemia’’, ‘‘myocardial infarction”,
‘‘ischaemic heart disease’’, ‘‘coronary heart disease’’, and ‘‘heart failure’’
(see Supplementary material online, Appendix S1). Only English language
publications were selected. Additionally, we manually searched the con-
ference abstracts of the American Heart Association, American College
of Cardiology, European Society of Cardiology, and Transcatheter Car-
diovascular Therapeutics to identify additional unpublished studies.
Finally, the bibliographies of identified studies and relevant reviewarticles
were screened for potentially suitable studies.
We included a study if: (i) it was a randomized, controlled trial; (ii)
patients were included with a clinical diagnosis of STEMI, treated with
percutaneous coronary intervention (PCI); (iii) a single intracoronary in-
fusion of autologous BMC (irrespective of the type and number of iso-
lated cells) within 1 month after STEMI was compared with a control
arm not receiving BMC (e.g. infusion of control media or standard
treatment). Studies were excluded if: (i) there were ,30 participants
in the cell therapyarm; (ii) follow-up was,3 months; (iii) BMCs were cul-
tured in vitro for longer than 1 day prior to intracoronary infusion, or (iv)
granulocyte colony-stimulating factor or macrophage colony-stimulating
factor was administrated as co-intervention.
Study identification was done by two independent reviewers and dis-
agreement was resolved by a third reviewer. A total of 26 randomized
clinical trials were identified through literature search (Figure 1 and see
Supplementary material online, Appendix S2). Out of these 26 studies,
16 had a cell therapy arm of 30 patients or more. Eventually, these 16
studies 5–7,9–21 all agreed to participate in this collaborative overview
and meta-analysis. They provided the requested data, and vouched for
the correctness of the data.
Endpoints, subgroups, and data assembly
The following three endpoints were investigated in the analysis: change in
LVEF (in %), LVESVI (in mL/m2), and LVEDVI (in mL/m2) from baseline to
Figure 1 Flow diagram of studies included in this meta-analysis.
RCTs, randomized controlled trials. See Supplementary material
online, Appendix S2 for a list of identified studies.
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follow-up. The preferred follow-up duration was 6 months. If not avail-
able, outcome at 3 or 4 months was used.
The following subgroups were defined by the baseline characteristics :
(i) age,55 years/≥55 years, (ii) diabetes mellitus yes/no, (iii) symptoms
to PCI time ,6 h/≥6 h, (iv) infarct-related artery left anterior descend-
ing artery/right coronary artery or left circumflex artery, (v) baseline
LVEDVI ,100 mL/m2/≥100 mL/m2, (vi) baseline LVEF ,40%/≥40%,
(vii) infarct size ,20 g/≥20 g on magnetic resonance imaging (MRI),
and (viii) MVO presence/absence on MRI. Furthermore, we requested
data on (ix) time from primary PCI to cell infusion ,7 days/≥7 days
and (x) total number of injected mononuclear BMC , 108/≥108. The
subgroups cut-off points were chosen based on the results of the previ-
ous cell therapy studies. Lastly, we compared two trial characteristics,
namely type of imaging modality (MRI vs. other) and study design
(double-blinded randomized controlled trials compared with open
label studies).
The principal investigator of each identified trial provided summary
data (numberofpatients andmean+ standarddeviation)of the threedif-
ferent endpoints and 10 different pre-specified subgroups.
For the current analysis, subgroups and baseline timing of the measure-
ment of LV function were defined as reported in each of the individual
trials. When several methods were used for outcome assessment, MRI
data were preferentially included in the analysis, followed by single
photon emission computed tomography, echocardiography and LV angi-
ography.
Statistical analysis
An overall meta-analysis was performed of the change in the three out-
comes (LVEF, LVESVI, and LVEDVI), based on random-effects models
using the method described byDerSimonian and Laird 22. Results arepre-
sented as absolute changes from baseline to follow-up, with their 95%
confidence intervals (CIs), per subgroup. Differences in treatment
effects between subgroups were tested with the heterogeneity test
from Review Manager version 5.0. This test is based on the notion of per-
forming a test for heterogeneity across subgroups rather than across
studies. It measures the extent of inconsistency across the subgroups’
results, and is interpreted as approximately the proportion of total vari-
ation in subgroup estimates that is due to genuine variation across sub-
groups rather than sampling error. For the subgroup based on infarct
size on MRI, the analysis was restricted to those six trials that had these
data.7,11,13,15,16,21,23 The presence or absence of MVO on MRI was avail-
able only in seven trials.6,7,11,15– 17,19,21 For the analysis regarding time
from primary PCI to cell infusion ,7 days/≥7 days and total number
of injected mononuclear BMC , 108/≥108, the specific BMC therapy
group was compared with controls in which sham infusion was per-
formed. In trials where no sham infusion was performed, the comparator
was compared with the entire control group. In the analysis of total
number of injected mononuclear BMC , 108/≥108, we excluded
three studies which used nucleated BMC or selected CD34+/CXCR4+
cells.5,20,21 Subgroup analyses were not adjusted for multiple testing.
Results
The participating trials randomized 1641 patients to intracoronary
cell therapy (n ¼ 984)or standard therapy (n ¼ 657).Characteristics
of the studies included in this review are listed in Table 1. The mean
age across studies ranged from 50 to 61 years. Six studies included
only patients with an anterior myocardial infarction. All STEMI
patients were treated with primary PCI, except in the FINCELL
study where patients were treated with thrombolysis first and later
with PCI and cell infusion.12 Six studies performed BMC aspiration
in the control group and seven studies performed sham infusion.
Three trials did not infuse mononuclear BMCs but selected
CD34+/ CXCR4+ cells or nucleated BMC, respectively.5,20,21 Meth-
odological quality assessment of included studies is available in see
Supplementary material online, Appendix S3. Trials fulfilled our
markers of validity.
In this analysis, 1494 patients had complete baseline and follow-up
LVEF measurement, 1427 patients complete LVEDVI measurements
(five patients were missing from one trial5 and LVEDVI was not avail-
able in another trial n ¼ 6220) and 1349 patients complete LVESVI
measurements (five patients missing from one trial5 and LVESVI
data was not available in two trials, n ¼ 62 and n ¼ 7812,20).
The absolute incremental improvement in LVEF was greater
among BMC-treated patients compared with controls: 2.55% in-
crease (95% CI: 1.83 to 3.26, P, 0.001), Figure 2. There was hetero-
geneity across all three outcomes namely change in LVEF, LVEDVI,
and LVESVI (respectively, I2 ¼ 84%, I2 ¼ 64%, and I2 ¼ 70%) (see
Supplementary material online, Appendix S4).
Patient characteristics
Treatment benefit in terms of LVEF improvement was more pro-
nounced in patients with baseline LVEF, 40% (5.30%, 95% CI:
4.27 to 6.33) compared with LVEF ≥40% (1.45%, 95% CI: 0.60 to
2.31, P, 0.001). Also, patients ,55 years of age had more benefit
from BMC therapy (3.38%, 95% CI: 2.36 to 4.39) compared with
patients age ≥55 years (1.77%, 95% CI: 0.80 to 2.74, P ¼ 0.03). No
significant interaction was observed between other subgroups and
LVEF.
The overall effect of change of LVEDVI was23.17 mL/m2 in favour
of BMC treatment (95% CI: 24.86 to 21.47, P ≤ 0.001, Figure 3).
This decrease was more pronounced in patient with age ,55 years
(25.70 mL/m2, 95% CI: 29.18 to 22.21), compared with patients
≥55 years of age (21.13 mL/m2, 95% CI:24.58 to 2.32, P ¼ 0.001).
There was a significant decrease in change of LVESVI in the BMC
group compared with the control group with a treatment effect of
22.60 mL/m2 (95% CI: 23.84 to 21.35, P, 0.001, Figure 4).
Again, patients with age ,55 years benefit most from BMC com-
pared with age ≥55 years (24.47 mL/m2, 95% CI: 27.32 to 21.62
vs. 20.82 mL/m2, 95% CI: 23.31 to 1.67, P ¼ 0.002). Also, patients
with baseline LVEF ,40% had a more pronounced decrease in
LVESVI (24.74 mL/m2, 95% CI: 210.23 to 0.74) compared with
LVEF ≥40% (20.91 mL/m2, 95% CI: 22.48 to 0.66, P, 0.001).
There was also an interaction between baseline LVEDVI and treat-
ment effect. Patients with a smaller EDV at baseline had less treat-
ment effect.
Trial characteristics
There was no difference in LVEF improvement between patients
treated with cell infusion ,7 days from primary PCI compared
with ≥7 days (1.46%, 95% CI: 0.41 to 2.51 vs. 2.69%, 95% CI: 1.80
to 3.58, P ¼ 0.08). Furthermore, we found no difference in LVEF im-
provement comparing patients with number of injected mono-
nuclear BMC of ,108 compared with ≥ 108 (2.80%, 95% CI: 0.79
to 4.80 vs. 0.58%, 95% CI: 20.44 to 1.59, P ¼ 0.05), Table 2.
Studies, using MRI as LV function assessment had a smaller treatment
effect in LVEF when compared with non-MRI studies (0.16% 95%
CI: 20.88 to 1.20 vs. 4.67%, 95% CI: 3.69 to 5.66, P, 0.001).
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Table 1 Characteristics of individual studies included in this review
Author (year) N BMC
vs.
control
Mean
age
(years)
Mean
Baseline
LVEF (%)
Days
from
onset
STEMI to
BMC
infusion
BMC
aspiration/
Sham
infusion in
control arm
Cell type Number
of injected
cells
(x108)
Volume
bone
marrow
aspiration
(mL)
Imaging
modality for
endpoint
assessment
Days from
STEMI to
baseline
LVEF
assessment
Core lab
assessment
of imaging
endpoint
Follow-up
(months)
Cao et al. (2009) 86 1:1 51 Tx) 41+3 7 No/Yes MN BMC 0.5+0.1 40 2D-TTE 7 No 6
C) 41+3
Grajek et al. (2010) 45 2:1 50 Tx) 45+10 4–6 No/No MN BMC 4.1+1.8 80+30 EF-RNV 4–6 No 6
C) 43+7
Hirsch et al. (2010) 134 1:1 56 Tx) 44+9 3–7 No/No MN BMC 3.0+1.6 60 MRI 3 (2–4) Yes 4
C) 42+8
Huikuri et al. (2008) 80 1:1 59 Tx) 59+11 3+2 Yes/Yes MN BMC 4.0+2.0 80 LV Angio
(biplane)
During PCI Yes 6
C) 62+12
Janssens et al. (2006) 67 1:1 57 Tx) 49+7 Within 1
day
Yes/Yes MN BMC 3.0+1.3 130+22 MRI 4 (3–5) No 4
C) 47+8
Lunde et al. (2006) 100 1:1 57 Tx) 55+14 4–8 No/No MN BMC 0.7 (0.5–
1.3)
50 MRI 19+4 No 6
C) 54+12
Plewka et al. (2009) 60 2:1 56 Tx) 35+6 7+2 No/No MN BMC 1.4+0.5 100 2D-TTE 3 No 6
C) 33+7
Roncalli et al. (2010) 101 1:1 56 Tx) 37+10 9+1 No/No MN BMC 1.0+0.09 50 MRI 7+2 Yes 3
C) 39+9
Schachinger et al. (2006) 204 1:1 56 Tx) 48+9 4+1 Yes / Yes MN BMC 2.4+1.7 50 LV angio
(biplane)
4+1 Yes 4
C) 47+10
Su¨rder et al. (2013) 200 2:1 58 Tx) 36+10 5–7 No/No MN BMC 1.5+1.2 68+15 MRI 6 (4 –8) Yes 4
C) 40+10 21–28
Tendera et al. (2009) 200 2:1 57 Tx) 40+10 3–12 No/No MN BMC 1.8 50–70 MRI 4–15 No 6
C) 40+9 Selected CD34+/
CXCR4+ cells
0.02 100–120
Traverse et al. (2010) 40 3:1 54 Tx) 49+10 5+2 Yes/Yes MN BMC 1.0 50–70 MRI 3+2 No 6
C) 49+9
Traverse et al. (2011) 87 2:1 57 Tx) 49+12 17 (16–20) Yes/Yes MN BMC 1.5+0.2 80–90 MRI 17 Yes 6
C) 45+10
Traverse et al. (2012) 120 2:1 57 Tx) 45+11 3 (3–4) Yes/Yes MN BMC 1.5+0.2 80–90 MRI 3 Yes 6
C) 45+11 8 (7–8)
Turan et al. (2012) 62 2:1 61 Tx) 43+10 7 No/No Nucleated BMC 96+32 120 LV Angio
(biplane)
7 No 3
C) 45+10
Wollert et al. (2004) 60 1:1 56 Tx) 50+10 6+1 No/No Nucleated BMC 25+9 128+33 MRI 4+2 No 6
C) 51+9
BMC, bone marrow cells; EF-RNV, ejection fraction radionuclide ventriculography; LVEF, left ventricular ejection fraction; LV, left ventricle; LVangio, left ventricular angiography; MN BMC, mononuclear bone marrow cells; MRI, magnetic resonance
imaging; N, number of patients; PCI, percutaneous coronary intervention; STEMI; ST-segment elevation myocardial infarction; TTE, transthoracic echocardiogram.
Tx, treatment arm; C, control arm.
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There was no clear interaction between study design (blinded 1.36%
95% CI: 20.04 to 2.76 vs. open label 2.97%, 95% CI: 2.14 to 3.80,
P ¼ 0.05). These results were largely consistent in LVEDVI and
LVESVI (Table 2).
Discussion
In this collaborative meta-analysis, we found that autologous BMC
infusion is associated with a moderate but statistically significant
improvement of LV systolic function and remodelling in patients
after STEMI. This is reflected by a larger increase in LVEF and a
greater decrease in LVESVI and LVEDVI in the treated population.
In additional subgroup analyses, younger patients and patients with
more depressed LVEF at baseline had the largest benefit from BMC
infusion.
Previous conventional meta-analyses have reported similar or
somewhat larger benefit from BMC infusion then we observed.
These meta-analyses reported, incremental LVEF changes of
2.7%24 and 3.02 to 4.0%25 in the most recent meta-analysis.
However, the last and most recent meta-analysis included all patients
Figure 2 Pooled improvement of left ventricular ejection fraction (LVEF) of included cell therapy trials assessing different subgroups. CI, confi-
dence interval; IRA, infarct-related artery; LAD, left anterior descending artery; LCX, left circumflex artery; LVEDVI, left ventricular end-diastolic
volume index; LVEF, left ventricular ejection fraction; MVO, microvascular obstruction; PCI, percutaneous coronary intervention; RCA, right cor-
onary artery. ¥ frequencies can vary across subgroups due to missing baseline characteristics values. *P-value for subgroup differences.
Impact of intracoronary bone marrow cell therapy on left ventricular function 993
with ischaemic heart disease, irrespective of study design (cohort
study or randomized trials).25 Also, this meta-analysis conducted
by Jeevanantham et al. did not include three large randomized con-
trolled trials (BONAMI, HEBE, and REGENT trial) that were included
in our analysis. Moreover, we have included only trials with at least 30
patients in the treatment arm. Most importantly, the present
collaborative meta-analysis is the first one based on original data as
provided by the principal investigators of the included trials. This
increases accuracy and also allows subgroup analysis.
In our analysis, younger patients benefit more from cell therapy in
terms of LV remodelling. Ageing is a significant predictor of impair-
ment of endothelium-dependent vasodilation and there is an
Figure3 Pooled improvement of left ventricularend-diastolic volume index (LVEDVI) of included cell therapy trials assessing different subgroups.
CI, confidence interval; IRA, infarct related artery; LAD, left anterior descending artery; LCX, left circumflex artery; LVEDVI, left ventricular end-
diastolic volume index; LVEF, left ventricular ejection fraction; MVO, microvascular obstruction; PCI, percutaneous coronary intervention; RCA,
right coronary artery. ¥ frequencies can vary across subgroups due to missing baseline characteristics values. *P-value for subgroup differences.
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increased risk of atherosclerotic disease and poor outcomes in older
patients. The accumulation of risk factors in the older population is
linked to a decrease in both the absolute number as well as the func-
tion of stem cells.26
However, ageing itself seems to have a very strong influence on
stem cell function and is accompanied by a decline in the homeostatic
and regenerative capacityof all tissues and organs.27 Bothexperimen-
tal as well as clinical studies have shown lower absolute numbers as
well as functionality of stem cells with increasing age.8,28 Bone
marrow cells isolated from younger-aged rats showed increased
efficacy in restoring LV function after myocardial infarction when
compared with BMCs isolated from middle-aged rats.28
In patients with chronic ischaemic heart disease, a similar relation
between age and stem cell function has been shown.29,30 In the con-
ducted BMC therapy clinical trials, autologous BMCs are typically har-
vested from older patients who have recently suffered a myocardial
infarction. In contrast, experimental studies in rodent models typically
utilize donor BMCs isolated from young, healthy, inbred mice that are
not the recipients. It has been postulated that this explains the much
greater benefit of BMC therapy as observed in experimental studies.31
Figure 4 Pooled improvement of left ventricular end-systolic volume (LVESVI) of included cell therapy trials assessing different subgroups. CI,
confidence interval; IRA, infarct-related artery; LAD, left anterior descending artery; LCX, left circumflex artery; LVEDVI, left ventricular end-
diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; MVO, microvascular obstruction;
PCI, percutaneous coronary intervention; RCA, right coronary artery. ¥ frequencies can vary across subgroups due to missing baseline character-
istics values. *P-value for subgroup differences.
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This might also have important implications for the therapeutic ap-
plication of cell therapy. Future research should therefore focus on
elucidating the crucial differences between young and aged BMCs
and to reverse or alter these characteristics before delivery in a clin-
ical setting.
In addition to younger age, we observed that patients with a more
severely depressed LVEF at baseline had larger benefit from cell
therapy. In fact, the effect in patients with an EF over 40% was prac-
tically non-existent, whereas in the group of patients with an EF
,40% the increase was substantial showing an improvement of 5%.
It is conceivable that such an improvement could alter the clinical
outcome in this high-risk population. Again, this has implications
for the design of future clinical trials. Especially at the present time,
when most studies are designed as proof-of-principle studies
instead of large clinical-outcome studies, the selection of patients is
of utmost importance and should contain subjects with the largest
potential benefit of the intervention.
Although reduced LVEF is associated with the presence of MVO
and larger MRI infarct sizes, we did not find an association between
the presence of MVO or infarct size and the effects of BMC infusion.
However, these MRI parameters were only present in ,37% of the
patients included in this analysis and therefore results should be inter-
preted with caution.
Diabetes mellitus is one of the key risk factors for coronary artery
disease, and its prevalence is expected to increase in the coming
years. Diabetes mellitus leads to dysfunction of the endothelium
and the microcirculation. Theoretically this could lead toadiminished
response to BMC infusion, hampering adhesion and homing of these
cells to the area of interest. Also the functionality and the absolute
numberof stemcells are reduced in diabetes mellitus.32,33 The reduc-
tion in cells was directly related to levels of HbA1c.33 Another study
showed that the reduced number of CD34+KDR+ cells was asso-
ciated with the severity of diabetic vasculopathy.34 Nevertheless,
we did not observe a relationship between the presence of diabetes
mellitus and efficacy of BMC infusion in our analysis. It should be
noted though that our study population consisted of ,16% of
patients with diabetics.
Although the effect of BMC infusion on LVEF seems to be small it
should be noted that other treatment modalities such as beta-
blocker therapy or direct revascularization also have a relatively
small influence on LVEF improvement.35 The question remains
what the long-term effects of a single intracoronary BMC infusion
are on LV function and remodelling and clinical outcomes. Additional
meta-analyses are performed to address this question,24,36 but
studies with long-term follow-up still remain limited. The large
BAMI trial, funded by the European Union, will investigate BMC
therapy in a randomized controlled trials with primary clinical end-
points in a STEMI population with 3000 patients and a LVEF ,45%
(NCT01569178). Lastly, several different strategies of cell isolation
and infusion have been applied and it yet remains to be determined
which is the most effective regimen.
Limitations
There are some limitations to our analysis that should be taken into
account. As with any meta-analysis, limitations to the method include
heterogeneity across trials. In particular, there are differences in
terms of treatment characteristics including used cell dosage, cell iso-
lation protocols, storage methods, and image modalities. Moreover,
in our analysis, we have excluded trials with a cell therapy arm ,30
participants [number of excluded patients is 322 (16%)]. We
excluded the smaller trials for several reasons. First, we believe
that subgroup assessment in these trials is less valuable due to
small numbers. Secondly, we feel that publication bias is a larger
problem in these small trials. Third, to our opinion, cell therapy
involves a comprehensive protocol that involves a learning curve.
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Table 2 Treatment effect of different trial characteristics included in this meta-analysis
LV ejection fraction (%) LV end-diastolic volume index (mL/m2) LV end-systolic volume index (mL/m2)
n Treatment
effect (95% CI)
P-value* n Treatment
effect (95% CI)
P-value* n Treatment
effect (95% CI)
P-value*
Time from PCI to cell infusion
,7 days 836 1.46 (0.41 to 2.51) 0.08 802 23.53 (25.89 to 21.18) 0.62 802 22.88 (24.70 to 21.06) 0.41
≥7 days 769 2.69 (1.80 to 3.58) 640 24.36 (26.66 to 22.05) 640 23.94 (25.69 to 22.19)
Total number of injected BMC
,1 × 108 314 2.80 (0.79 to 4.80) 0.05 314 24.72 (28.15 to 21.29) 0.34 314 26.36 (29.46 to 23.27) 0.01
≥1 × 108 1005 0.58 (20.44 to 1.59) 1005 22.78 (24.85 to 20.70) 927 21.97 (23.58 to 20.36)
Imaging modality for LV function
MRI 981 0.16 (20.88 to 1.20) ,0.001 976 21.50 (23.82 to 0.82) 0.02 976 0.16 (21.54 to 1.85) ,0.001
Other 513 4.67 (3.69 to 5.66) 451 25.63 (28.11 to 23.15) 373 25.85 (27.69 to 24.01)
Study design
Blinded 558 1.36 (20.04 to 2.76) 0.05 558 21.93 (24.96 to 1.09) 0.24 480 22.41 (24.60 to 20.21) 0.84
Open label 936 2.97 (2.14 to 3.80) 869 24.11 (26.16 to 22.06) 869 22.69 (24.20 to 21.17)
BMC, bone marrow cells; CI, confidence interval; LV, left ventricular; MRI, magnetic resonance imaging; n, number of patients; PCI, percutaneous coronary intervention.
*P-value for subgroup differences.
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Conclusion
This is, to our knowledge, the first collaborative meta-analysis to
assess the effects of intracoronary BMC therapy. Intracoronary
BMC therapy leads to a modest but significant improvement of LV
function in patients after STEMI. Patients of younger age and with a
more severely depressed LVEF showed the largest benefit. This
should be taken into account when designing future trials using intra-
coronary BMC infusion as an adjunctive therapy for STEMI. Most im-
portantly, trials like the ongoing BAMI-trial that are powered to
determine the effects of BMC infusion on clinical endpoints need
to be awaited. Such trials will show whether the modest improve-
ment of LV function translates in true clinical benefit.
Supplementary material
Supplementary material is available at European Heart Journal online.
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